New Zealand’s Pharmaceuticals Management Agency PHARMAC will begin funding for the prostate cancer treatment abiraterone (Zytiga) from May 1, 2015, potentially benefiting up to 1,000 men annually. 9 April 2015
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a dossier assessment whether nintedanib (trade name Vargatef, from German family-owned pharma major Boehringer Ingelheim) offers an added benefit over the appropriate comparator therapy. 9 April 2015
Following a public comment period, the USA’s Federal Trade Commission has approved a final order settling charges that Swiss pharma major Novartis’ $16 billion acquisition of UK peer GlaxoSmithKline’s portfolio of cancer-treatment drugs likely would be anticompetitive. 9 April 2015
The diversity in the liver cancer drug pipeline could transform the treatment landscape within the next decade, according to a new report from business intelligence provider GBI Research. 8 April 2015
Swiss drug major Roche says the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic cervical carcinoma. 8 April 2015
Germany’s Merck KGaA and US pharma giant Pfizer have finalized their co-promotion agreement allowing the companies to co-promote Pfizer’s anaplastic lymphoma kinase inhibitor Xalkori (crizotinib). 7 April 2015
The US Food and Drug Administration has granted Breakthrough Therapy designation for US personalized cancer therapy specialist Clovis Oncology’s investigational agent rucaparib. 7 April 2015
Astellas Pharma and the USA’s University of Texas MD Anderson Cancer Center have signed an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML). 7 April 2015
Pharma regulator Health Canada has approved the use of US drugmaker Ariad Pharmaceuticals’ Iclusig (as ponatinib hydrochloride) in Canada. 7 April 2015
Swiss sdrug major Novartis has reached a settlement agreement with Juno Therapeutics over a chimeric antigen receptor technology (CAR-T) for oncology. 7 April 2015
USA-based Amgen (Nasdaq: AMGN), the world’s leading independent biotech firm, said today it has received approval from the European Commission for a new use of Vectibix (panitumumab). 6 April 2015
US drugmaker Medivation and Japanese major Astellas Pharma have released positive new top-line results from the Phase III STRIVE trial comparing Xtandi (enzalutamide) with bicalutamide, in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. 3 April 2015
Clinical-stage nanomedicines specialist BIND Therapeutics said Thursday that it has extended the terms of its global collaboration with US pharma giant Pfizer. 3 April 2015
Pharma giant Merck & Co has entered into a clinical trial collaboration with Syndax Pharmaceuticals to evaluate the safety and efficacy of combining Syndax’s entinostat with Merck’s Keytruda (pembrolizumab). 2 April 2015
Goldman Small Cap Research, a stock market research firm specializing on the small cap and microcap sectors, has issued a new article on PharmaCyte Biotech, a publicly-traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. 2 April 2015
The Australian government has announced a further A$75 million ($58 million) commitment to list three new drugs on the Pharmaceutical Benefits Scheme (PBS). 1 April 2015
A group of academic organizations and funders has entered an agreement with Swiss biopharmaceutical company Basilea Pharmaceutica (SIX: BSLN) to progress a new family of cancer drugs. 1 April 2015
Merck Serono, the biopharmaceutical arm of Germany’s Merck, and US biotech firm Intrexon Corp have entered into an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. 30 March 2015
The US Food and Drug Administration has granted priority review for Kyprolis (carfilzomib) from Amgen and has approved a label update for Zytiga (abiraterone acetate) from Janssen. 30 March 2015
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024